Did Pfizer's Obesity Shot Do Well Enough To Catch Lilly? - Investor's Business Daily

AI Summary1 min read

TL;DR

Pfizer's experimental obesity drug, Metsera, showed promising mid-stage trial results with up to 12.3% weight loss as a monthly treatment, but Pfizer stock dipped amid comparisons to Lilly's offerings.

Tags

Pfizerobesity drugMetseraclinical trialweight loss
  1. Did Pfizer's Obesity Shot Do Well Enough To Catch Lilly?  Investor's Business Daily
  2. Pfizer stock dips on Metsera mid-stage trial results  Axios
  3. Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial  CNBC
  4. Pfizer's experimental drug shows up to 12.3% weight loss in mid-stage trial  Reuters
  5. Pfizer unveils data on Metsera drug  statnews.com

Visit Website